This well-conducted review and individual patient data meta-analysis demonstrated the superior effectiveness of chemoradiotherapy compared to radiotherapy on survival, recurrence, progression and disease-free survival for cervical cancer. The results of the review are likely to be reliable.
Study selection
Randomised trials that compared concomitant cytotoxic chemoradiotherapy (with or without surgery) versus equivalent radiotherapy (with or without surgery) among previously untreated patients with cervical cancer. The primary outcome was overall survival. Locoregional progression and/or recurrence, disease-free survival and toxicity were treated as secondary endpoints where data were available. Trials that used non-cytotoxic treatments or hydroxyurea as the sole chemotherapy agent on the experimental arm were excluded.
Included women were mostly between 35 and 64 years old. Tumours were mostly squamous cell histology (89%), stage IIb (36%) or stage III (36%) and moderately differentiated (35%).
The authors did not stated how many reviewers performed study selection.
Assessment of study quality
All data were checked for validity, consistency, integrity of randomisation and follow-up. Inconsistencies were resolved and data were validated by the original trialists.
Data extraction
Individual time-to-event data was used to calculate hazard ratios (HR) for survival and recurrence outcomes. Binary data were used to calculate Peto odds ratios for response and toxicity outcomes on an intention-to-treat basis. Prespecified trial characteristics that included dose, duration, timing and type of chemotherapy (platinum based or not) were extracted. Individual patient characteristics that included tumour stage were extracted. Details of all subgroups were provided.
Methods of synthesis
Effects were pooled using stratified-by-trial fixed-effect and random-effects models. The effects of chemoradiotherapy within pre-specified trial and patient subgroups were explored by obtaining effect estimates for each subgroup within each trial. These effects were combined to provide overall subgroup effects. Χ 2 tests for interaction were used to explore the significance of differences between trial and patient subgroups. Heterogeneity was quantified using I 2 .
Results of the review
Individual patient data were available from 15 (3,452 women) of 25 eligible trials. These included 75% of eligible women, almost 80% of women in fluorouracil and/or mitomycin trials and 85% of women from trials of cisplatin-based chemotherapy. Data were obtained on 118 women excluded from the investigators original analyses. Median follow-up for living patients across all trials was 5.2 years.
Based on the 13 trials that compared chemoradiotherapy versus the same radiotherapy, there was a 19% relative reduction in risk of death with chemoradiotherapy (HR 0.81, 95% CI, 0.71 to 0.91) equivalent to a 6% improvement in five-year survival. There were similar benefits of chemoradiotherapy for disease-free survival (HR 0.78, 95% CI 0.70 to 0.87), five-year locoregional disease-free survival (HR 0.76, 95% CI 0.68 to 0.86), time to locoregional progression (HR 0.74, 95% CI 0.64 to 0.86) and metastases-free survival (HR 0.81, 95% CI 0.72 to 0.91). Insufficient data were available to assess response or late treatment toxicity.
Subgroup analyses based on overall survival found no evidence of a difference in size of effect of chemotherapy based on patient characteristics, dose, duration or type of chemotherapy. A larger survival benefit was seen for the two trials in which chemotherapy was administered after chemoradiotherapy. Heterogeneity was low in all analyses (I 2 <30%), although sensitivity analysis that included trials with additional control arm treatments led to statistically significant heterogeneity.
